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abstract
Over the past decade, improved personal protective equipment and medical support has reduced combat fatalities substantially among wounded war fighters. As a result, survivors are more likely to present with severe trauma to their arms and legs that will need multiple reconstructive surgeries or amputation during their recovery. The orthopaedic doctors caring for these wounded service personnel have been concerned by the fact that over 60% of these patients go on to form abnormal bone within the soft tissue of their injured limbs. This condition, known as Heterotopic Ossification (HO), causes pain, loss of mobility, and often requires additional surgeries to remove the rock hard tissue that has replaced their fat and muscle. While there are theories to explain why HO might occur, doctors still do not fully understand the mechanism(s) causing this disorder. Without knowing the mechanism, doctors find it difficult to predict which patients might be at risk for developing HO or to decide which drugs or treatments to use that would prevent HO from happening in these patients. The currently available treatments for HO have many undesirable side effects which can complicate the overall recovery process. The Specific Aims of this Idea Development proposal address these important questions by using blood samples collected from wounded warriors and civilians with bone injuries. The study will compare the blood samples between patients who either have or have not developed HO during the first year after their injury. The first experiments will ask, does the blood or wound fluid contain any proteins that can stimulate fat or muscle cells to form bone in the laboratory? This will test whether patients with HO have factors circulating in their blood or around the wound that specifically stimulate bone formation as compared to patients without HO. If this proves true, it will be an important step forward in understanding how HO occurs. The second experiments will ask, what is the identity of the protein(s) in the HO blood that might cause bone to form? The study will use a state of the art technique that can analyze all of the proteins in the blood and find out which ones are present. Using computer technology, researchers can then learn the name and function of these proteins of interest. This type of information will be of particular value to the orthopaedic surgeons caring for HO patients. The presence or absence of these proteins in the blood can be used to predict which patients might develop HO or to monitor HO treatment. Also, by knowing the names of the proteins involved in HO, doctors and pharmacists might be able to tell which drugs can be used to prevent HO formation at the time of injury. Wounded warriors and civilians would benefit directly from these advances since doctors would be able to prevent HO with a pill or drug or, at the very least, reduce the number of surgeries required to treat the condition when it happens. There would be minimal risk to wounded war fighters and civilian patients enrolled in this study. Patients would only be required to provide several extra tablespoons of blood to doctors during the weeks to months following their injury. This might cause a bruise but no other complications and would not interfere with their recovery in any way. It is predicted that this information could be used to improve patient care within 5 years or less after the study is completed. As a result, war fighters recovering from blast injuries in the future will have a better outlook than today's combat casualties. They will no longer have the same high risk of developing HO and can avoid the emotional, psychological and physical damage sustained as a result of multiple orthopaedic surgical procedures. As a result, the effort, time, and cost of wounded warrior's recovery from life threatening orthopaedic trauma could be substantially reduced and as such, accelerate their return to active duty.
INTRODUCTION:
Narrative that briefly (one paragraph) describes the subject, purpose and scope of the research. Heterotopic Ossification (HO), the ectopic formation of bone in soft tissues, has been found to complicate >60% of extremity war injuries in casualties from Afghanistan and Iraq. Elevated levels of circulating and local cytokines released in response to high energy blast injuries have been found to correlate with the onset of HO, indicating that the disease process will require early intervention; however, preventive therapies such as tissue radiation, bone morphogenetic protein antagonists, and cyclooxygenase inhibitors, carry substantial risks for patients recovering from orthopaedic trauma. Consequently, there is an as yet unmet medical need to develop assays of serum and wound fluid biomarkers to identify those patients at greatest risk of HO progression during their recovery. The current project is using liquid chromatography/mass spectroscopy, in combination with other cell and protein biological assays, to evaluate the serum and wound fluid from civilian and military orthopaedic trauma patients for the presence of cytokines or factors capable of inducing HO. The studies are focusing on a select set of candidate biochemical pathways (bone morphogenetic, cyclic AMP, Wnt) that have been implicated in genetic models of HO. The research team includes expertise in civilian and military orthopaedic surgery, adipose and bone marrow stromal/stem cell biology, proteomics and mass spectroscopy, and regenerative medicine. During the first year of the project, the scope of the study was expanded to include the analysis of serum samples from established murine (burn) and rat (blast injury) models of HO and these analyses will be used to complement and support the initially proposed studies of human serum. subjects have been recruited and seventeen remain actively enrolled. Eight of the seventeen subjects remaining in the study have developed radiographic evidence of HO in less than one year following the initial trauma event. This corresponds to an incidence of HO in civilian orthopaedic trauma patients of 47% based on those subjects remaining enrolled or 36% based on all subjects originally enrolled in the study. These values are lower than, but comparable to, the 65% incidence of HO observed in military orthopaedic trauma subjects. Ms. Cara Rowe was hired in September 2016 to replace Ms. Boos and will continue to recruit subjects moving forward. 4. An IRB protocol has been approved at LSUHSC-NO to perform a retrospective clinical study to assess frequency of heterotopic ossification in civilian orthopaedic trauma and elective surgical patients. Dr. Harry Molligan (PGY2, LSUHSC-NO) and Matt Fury (Medical Student LSUHSC-NO) are actively participating in this project and are nearing completion of their review of the patient records. 5. Serum collected from the civilian and military patients have been evaluated by mass spectroscopy. Follow up studies are being performed by western blot and ELISA to confirm the mass spectroscopy proteomic findings. Additional ELISA studies will be performed to determine the expression of those cytokines identified in military orthopaedic trauma patient serum samples as predictive of HO development. The ELISA kits required have been received at Tulane University and the assays will be performed within the next 6 to 12 months. Upon completion, this data will be compiled with relevant clinical and radiographic data into a manuscript describing the incidence of HO in a prospective study of civilian orthopaedic trauma. 6. Serum samples collected from murine (burn) and rat (blast injury) models of HO under approved IACUC protocols have been incorporated into the study design. The inclusion of these animal models will provide opportunities to better control the degree of injury and the timing of serum collection and, more important, will provide the team with access to serum samples that can be replaced (unlike the more limited and therefore valuable human specimens Two manuscripts are being prepared to report the human and rat serum proteome, respectively. These studies will describe the mass spectroscopy proteome as well as confirmatory secondary protein analyses (ELISA, western blot). The investigators
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have not yet decided on the appropriate journal(s) for submission. A comparable study of the murine burn model serum will be prepared when that data is complete.
Two manuscripts will be prepared to report the incidence of heterotopic ossification in a civilian population retrospectively (review of the LSUHSC records) and prospectively (analysis of the current civilian orthopaedic trauma patient cohort). The investigators have not yet decided on the journal(s) for submission. 
KEY RESEARCH ACCOMPLISHMENTS:

CONCLUSION:
Summarize the importance and/or implications with respect to medical and /or military significance of the completed research including distinctive contributions, innovations, or changes in practice or behavior that has come about as a result of the project. A brief description of future plans to accomplish the goals and objectives shall also be included.
The third year of this research project has continued to integrate productive and complementary activities across four distinct campuses. Critical established and validated assays necessary to complete the study goals were shared between campuses and used effectively to generate statistically significant and conclusive data. The team continues to advance its experimental findings to peer reviewed publication. The outcomes of the experiments now underway and/or nearing completion have begun to define biomarkers and signal transduction pathways involved in the onset of HO. These are being investigated and validated across species (human, mouse, rat) and will advance our understanding of the signal transduction pathways regulating osteogenesis in bone and soft tissue derived stromal/stem cells. In the coming year, under an approved no-cost extension, the investigative team will seek to achieve the following goals: 1. Publication of primary research manuscripts regarding the response of human ASC, BMSC and skeletal muscle cells to osteogenic inductive factors and human serum from HO and non-HO civilian and military patients in a time dependent manner. 2. Publication of a detailed LC/MS study of serum biomarkers in the rat and human with accompanying manuscript submissions. Similar studies on the murine HO serum proteome will be completed thereafter and prepared for publication. 3. Publication of HO incidence based on prospective and retrospective analyses of civilian orthopaedic trauma patients. 4 . Continue to present abstracts for poster and oral presentation at regional, national and international meetings from the investigative team.
PUBLICATIONS, ABSTRACTS, AND PRESENTATIONS:
a. List all manuscripts submitted for publication during the period covered by this report resulting from this project. Include those in the categories of lay press, peer-reviewed scientific journals, invited articles, and abstracts. Each entry shall include the author(s), article title, journal name, book title, editors(s), publisher, volume number, page number(s), date, DOI, PMID, and/or ISBN.
(1) Lay Press: None 
INVENTIONS, PATENTS AND LICENSES:
List all inventions made and patents and licenses applied for and/or issued. Each entry shall include the inventor(s), invention title, patent application number, filing date, patent number if issued, patent issued date, national, or international.
Nothing to report.
REPORTABLE OUTCOMES:
Provide a list of reportable outcomes that have resulted from this research. Reportable outcomes are defined as a research result that is or relates to a product, scientific advance, or research tool that makes a meaningful contribution toward the understanding, prevention, diagnosis, prognosis, treatment and /or rehabilitation of a disease, injury or condition, or to improve the quality of life. This list may include development of prototypes, computer programs and/or software (such as databases and animal models, etc.) or similar products that may be commercialized.
OTHER ACHIEVEMENTS:
This list may include degrees obtained that are supported by this award, development of cell lines, tissue or serum repositories, funding applied for based on work supported by this award, and employment or research opportunities applied for and/or received based on experience/training supported by this award. 
